MARKET EYE-Shasun Pharmaceuticals falls on Vertex drug warning

Thu Dec 20, 2012 2:03pm IST

Related Topics

Stocks

   

* Shasun Pharmaceuticals falls 6 percent after its
Vertex Pharmaceuticals warned on Wednesday its
hepatitis C drug Incivek, which is used in conjunction with two
other products, can cause serious, potentially fatal skin
reactions. 
* Shasun has a long-term agreement with Vertex for supply of
active pharmaceutical ingredient for the Hepatitis C drug.
* "There would be incremental impact on Shasun as about 25
percent of FY13 profits were expected to come in from Incivek
supply," said Surya Patra, an analyst tracking the sector at
Systematix Shares & Stocks.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Sundar Pichai Elevated

Sundar Pichai Elevated

Google's Pichai to oversee major products and services.  Full Article 

Need For Reforms

Need For Reforms

Euro zone risks "relapse into recession" without structural reforms - Draghi.  Full Article 

Diwali Sales

Diwali Sales

Gold sales jump about 20 pct for Diwali - trade body  Full Article 

World Bank Rival

World Bank Rival

Three major nations absent as China launches W.Bank rival in Asia  Full Article 

Wal-Mart India

Wal-Mart India

Murali Lanka appointed as Wal-Mart India operations chief  Full Article 

Health Of Lenders

Health Of Lenders

25 European banks set to fail health checks - sources.  Full Article 

Special Report

Special Report

Why Madrid's poor fear Goldman Sachs and Blackstone  Full Article 

U.S. Economy

U.S. Economy

Spectre of no-inflation world looms over Fed's return to normal  Full Article 

India Insight

India Insight

Kalki Koechlin on her role as a disabled girl in “Margarita, With a Straw”  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage